drug · antibody
tulisokibart
Phase 2updated 3mo agoby $MRK Merck & Co., Inc.🔗 ChEMBL
Phase 2community read0 votes
🐶 often sniffed alongside
top 3Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 4 investigational indications.
all catalysts(1)
Trials studying tulisokibart
- phase2Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
- phase3A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- phase3Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- phase2Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
- phase2A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
- phase2A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)
- phase2A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
- phase1A Study of MK-7240 in Healthy Participants (MK-7240-009)
News(5)
- Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcommsThe industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second qu…biospace · 9d ago
- Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b missThe anti-TL1A antibody from Merck's 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside seco…biospace · 10d ago
- J&J pharma leader to retire; Krystal slumps on gene therapy missJennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.biopharma_dive · 10d ago
- Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trialsA phase 2 trial of Merck & Co.’s anti-TL1A monoclonal antibody has missed its primary endpoint, closing off one avenue for expansion of an asset acquired in a $10.8 billion takeover. The setback wa…fiercebiotech · 10d ago
- ‘Reverse mergers are increasingly popular’: Caldera hops on Synlogic’s Nasdaq listingCaldera Therapeutics has struck a reverse merger with the publicly traded Synlogic and inked a $278 million financing deal, continuing the meteoric rise of the inflammatory bowel disease startup.fiercebiotech · 16d ago
Data sources
last refreshed 8m ago
Found something off?
comments(0)
5-min edit window · permanent after that